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he 6-O sulfation states of cell surface heparan sulfate
proteoglycans (HSPGs) are dynamically regulated to
control the growth and speciﬁcation of embryonic
progenitor lineages. However, mechanisms for regulation
of HSPG sulfation have been unknown. Here, we report on
the biochemical and Wnt signaling activities of QSulf1, a
novel cell surface sulfatase. Biochemical studies establish
that QSulf1 is a heparan sulfate (HS) 6-O endosulfatase
with preference, in particular, toward trisulfated IdoA2S-
GlcNS6S disaccharide units within HS chains. In cells, QSulf1
can function cell autonomously to remodel the sulfation of
cell surface HS and promote Wnt signaling when localized
T
 
either on the cell surface or in the Golgi apparatus. QSulf1
6-O desulfation reduces XWnt binding to heparin and HS
chains of Glypican1, whereas heparin binds with high afﬁnity
to XWnt8 and inhibits Wnt signaling. CHO cells mutant for
HS biosynthesis are defective in Wnt-dependent Frizzled
receptor activation, establishing that HS is required for
Frizzled receptor function. Together, these ﬁndings suggest
a two-state “catch or present” model for QSulf1 regulation of
Wnt signaling in which QSulf1 removes 6-O sulfates from
HS chains to promote the formation of low afﬁnity HS–Wnt
 
complexes that can functionally interact with Frizzled
receptors to initiate Wnt signal transduction.
 
Introduction
 
Heparan sulfate proteoglycans (HSPGs)* are major compo-
nents of the extracellular matrix that regulate transmission of
developmental signals and also are implicated in the patho-
physiology of diseases, including cancer, in which signals
and tissue interactions malfunction (Selva and Perrimon,
2001; Nybakken and Perrimon, 2002). HSPGs are classified
as soluble and membrane-intercalated subtypes such as
Glypicans and Syndicans, which are composed of a core
protein decorated with covalently linked heparan sulfate (HS)
chains (Bernfield et al., 1999). HS chains are polysaccharides
that are synthesized in the Golgi apparatus and contain
repeating disaccharide units of uronic acid linked to gluco-
samine (Bernfield et al., 1999; Prydz and Dalen, 2000). The
disaccharide units are selectively sulfated at the N, 3-O, and
6-O positions of glucosamine and the 2-O position of
uronic acid residues by actions of sulfotransferases in the
Golgi apparatus. After biosynthesis, HSPGs are secreted to
the cell surface or the extracellular matrix, where they have
signaling and matrix functions (Bernfield et al., 1999;
Nybakken and Perrimon, 2002). Cell surface HSPGs are
also shredded and/or internalized by an endocytosis pathway
involving HS degradation by catabolic enzymes, including
exosulfatases for removal of terminal sulfates on sugar resi-
dues (Yanagishita and Hascall, 1992; Bai et al., 1997).
The extracellular signaling activities of HSPGs are mediated
by their HS chains, which bind a diversity of developmental
signaling ligands (Nybakken and Perrimon, 2002; Rapraeger,
2002). The sulfation states of HS chains influence their inter-
actions with signaling molecules. FGF signal transduction is
dependent on the sulfation of 2-O and 6-O positions on HS
chains. The 2-O sulfation is required for bFGF binding to
heparin and 6-O sulfation for bFGF-dependent dimerization
and activation of the FGFR1 receptor, as revealed by both
biochemical (Pye et al., 2000; Jemth et al., 2002) and the
crystal structure studies of FGF–FGFR1–heparin ternary
complexes (Schlessinger et al., 2000). Wnt (Wingless [Wg])
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signaling also is controlled by HS sulfation. The 
 
Drosophila
sulfateless
 
 gene encodes an HS N-deacetylase/N-sulfotrans-
ferase, and 
 
sulfateless
 
 mutants are completely deficient in HS
sulfation and have disrupted Wg signaling (Lin and Perri-
mon, 1999; Toyoda et al., 2000). Furthermore, chlorate,
which is a metabolic inhibitor of HS sulfation, blocks Wnt
(Wg) signaling in 
 
Drosophila
 
 and mammalian cultured cells
(Reichsman et al., 1996; Dhoot et al., 2001). Therefore, the
signaling activities of HSPGs in extracellular signaling are
regulated by HSPG sulfation.
HS sulfation is dynamically regulated and tissue specific.
In particular, the 6-O sulfates of HSPGs are precisely posi-
tioned, leading to microheterogeneity along the length of
HS chains (Brickman et al., 1998; Merry et al., 1999; Sa-
faiyan et al., 2000). Changes in HSPG 6-O sulfation have
been correlated with regulatory changes in FGF signal-
ing during neural development and tumor transformation
(Brickman et al., 1998; Jayson et al., 1999). How the het-
erogeneous sulfation patterns of HSPGs are generated and
dynamically maintained during the development has not
previously been known. Most enzymes involved in Golgi-
based HS biosynthesis and lysosomal HS degradation appear
to be constitutively expressed in different tissues (Prydz and
Dalen, 2000), and it has so far been difficult to pinpoint
their roles as HS sulfation regulators. Furthermore, previ-
ously characterized HS sulfatases are exosulfatases that re-
move terminal sulfates from HS chains (Kresse et al., 1980;
Raman et al., 2003) and, therefore, cannot generate in-
tramolecular microheterogeneity of HS sulfation. Therefore,
although HS sulfation is dynamically regulated to create HS
microheterogeneity on HSPGs (Lindahl et al., 1998; Esko
and Lindahl, 2001), mechanisms for regulation of HSPG
sulfation remain unknown.
In this paper, we report on the biochemical and Wnt sig-
naling activities of a novel extracellular sulfatase, QSulf1,
which is a candidate developmental regulator of HSPG sul-
fation in embryonic progenitor lineages (Dhoot et al.,
2001). QSulf1 has an enzymatic domain homologous to ly-
sosomal HS-specific GlcNR 6-O sulfatase (GlcNR6Sase),
which functions in the lysosomal degradation of HS. Unlike
GlcNR6Sase, QSulf1 has an NH
 
2
 
-terminal secretion signal
peptide and hydrophilic domain for secretion and docking
the cell surface. Homologues of QSulf1 have been identified
in both vertebrates and invertebrates (Dhoot et al., 2001;
Morimoto-Tomita et al., 2002; Ohto et al., 2002), and a
second related family member, Sulf2, has been identified in
mammals (Morimoto-Tomita et al., 2002) and birds (un-
published data). QSulf1 is essential for activation of the
myogenic regulator 
 
MyoD
 
 for specification of muscle pro-
genitors in embryonic somites and promotes Wnt-depen-
dent signaling in myoblasts (Dhoot et al., 2001). Mutations
that disrupt an essential N-formylglycine modification in
the catalytic site blocked QSulf1 function in the Wnt signal-
ing pathway, suggesting that QSulf1 functions as an enzy-
matically active sulfatase. We now show that QSulf1 is an
HS-specific 6-O endosulfatase with a high degree of sub-
strate specificity for 6-O–sulfated disaccharides of HS chains
of HSPGs, including Glypican1, which is required for Wnt
signaling (Lin and Perrimon, 1999; Tsuda et al., 1999; Baeg
et al., 2001). QSulf1 localized on the cell surface or targeted
 
in the Golgi apparatus is functionally active in remodeling
the 6-O sulfation states of HSPGs on the cell surface and
promotes Wnt signaling. Biochemical and cell biological
studies of Wnt–HS binding and Frizzled receptor activity
reveal that QSulf1 functions as part of a two-state “catch or
present” mechanism to regulate Wnt signaling, specifically
to modulate the binding affinity of Wnts to HS chains on
HSPGs to promote the HS-mediated presentation of Wnt
ligand to its Frizzled receptor to initiate signaling.
 
Results
 
QSulf1 is an HS-specific sulfatase
 
QSulf1 has sequence homology with the catalytic domain of
GlcNR6Sase, a 6-O exosulfatase involved in the lysosomal ca-
tabolism of HS. Mutation of a critical Cys89 in the QSulf1
catalytic domain blocks its Wnt signaling activity, suggesting
that QSulf1 is an enzymatically active sulfatase (Dhoot et al.,
2001). To investigate the enzymatic activity of QSulf1 on sul-
fated glycosaminoglycan (GAG) substrates, 293 cells were
metabolically labeled with [
 
35
 
S]SO
 
4
 
, and high molecular mass,
 
35
 
S-labeled GAGs were isolated for enzymatic analysis. Myc-
tagged QSulf1 expressed by transient transfection of 293 cells
was isolated and purified 15-fold by affinity purification on
Myc beads, as determined by Western blot analysis (unpub-
lished data). QSulf1 in cell lysates and Myc bead–purified
preparations was incubated with [
 
35
 
S]GAGs and then assayed
for [
 
35
 
S]SO
 
4
 
 release using a spin column method to monitor
enzyme activity. As controls, cell extracts were prepared from
293 cells transfected with either empty expression vector or a
vector expressing mutant QSulf1(C-A), which has Ala sub-
stitutions at Cys89,90 to block N-formylglycine modifica-
tion, which is required for catalytic activity of all sulfatases
(Schmidt et al., 1995). Wild-type QSulf1 was enzymatically
active and released 
 
 
 
5% of [
 
35
 
S]SO
 
4
 
 from the [
 
35
 
S]GAG sub-
strate (Fig. 1 A). QSulf1 activity is optimal at pH 7.5 (Fig. 1
F), requires Mg
 
2
 
 
 
, is enhanced by Pb
 
2
 
 
 
, and is inhibited by
25 mM phosphate or sulfate. Control cell extracts prepared
from cultures transfected with pAG empty vector or mutant
QSulf1(C-A) were inactive in [
 
35
 
S]SO
 
4
 
 release, confirming the
requirement of that Cys89,90 and N-formylglycine modifica-
tion for enzyme activity and showing that cell extracts do not
have measurable endogenous sulfatase activities. As GAGs are
a mixture of HS and chondroitin sulfate (CS), [
 
35
 
S]GAGs
were differentially treated with heparinases I and II and chon-
droitinase ABC to selectively deplete HS or CS, which ac-
counted for 78 and 22% of radioactivity in [
 
35
 
S]GAG prepa-
rations, respectively. QSulf1 was fully active in [
 
35
 
S]SO
 
4
 
release from HS-enriched [
 
35
 
S]GAGs (Fig. 1 B) and was inac-
tive on CS-enriched [
 
35
 
S]GAGs (Fig. 1 C), establishing that
QSulf1 is an HS sulfatase. QSulf1 is also active in HS desulfa-
tion on metabolically labeled [
 
35
 
S]Glypican1 (Fig. 1 D), a cell
surface HSPG that mediates Wnt signaling (Lin and Perri-
mon, 1999; Tsuda et al., 1999; Baeg et al., 2001), and, there-
fore, is the likely cellular substrate for QSulf1.
 
QSulf1 is a 6-O endosulfatase
 
To define the substrate specificity of QSulf1, we assayed ra-
diolabeled disaccharide products generated by deaminative
cleavage of [
 
35
 
S]GAG preparations (Shively and Conrad,T
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1976; Rong et al., 2001) after incubation with wild type and
(C-A) mutant forms of QSulf1 and with control cell extracts.
Four major [
 
35
 
S]disaccharide products were resolved by
HPLC chromatography: GlcA-GlcNS6S, IdoA-GlcNS6S,
IdoA2S-GlcNS, and IdoA2S-GlcNS6S (Table I). QSulf1 is
preferentially active in the 6-O desulfation of IdoA2S-
GlcNS6S units, with less pronounced effect on GlcA-
GlcNS6S and no detectable effect on IdoA-GlcNS6S (Table
I). In these assays, GlcA-GlcNS6S and IdoA2S-GlcNS6S are
significantly decreased as a percentage of total radioactivity
by 
 
 
 
20 and 
 
 
 
32%, respectively, with a parallel 
 
 
 
50% in-
crease of the reaction product IdoA2S-GlcNS. QSulf1 did
not desulfate IdoA-GlcNS6S, even when enzyme reactions
were performed for extended times. These findings show
that QSulf1 is an HS-specific 6-O sulfatase with substrate
specificity for a subset of 6-O–sulfated disaccharide sub-
strates in HS. The disaccharide analyses also establish that
QSulf1 is an endosulfatase, based on the quantitative extent
of its activity on HS chains and its specificity for selected
6-O disaccharide substrates located at internal sites along HS
chains. In contrast to the lysosomal GlcNR6ase, which func-
tions exclusively as an exoenzyme on nonreducing-terminal
GlcNR6S residues (Kresse et al., 1980), QSulf1 desulfates
GlcNS6S residues located on the reducing side of GlcA
units, hence functioning in an endolytic mode (Table I).
Furthermore, QSulf1 does not desulfate the monosaccharide
substrate N-acetylglucosamine 6-O sulfate, consistent with
its activity as an endosulfatase, in contrast to the lysosomal
exosulfatase GlcNR6Sase, which actively hydrolyzes this
monosaccharide substrate both at pH 5.5 and 7.5 (Reissig et
al., 1955; He et al., 1993) (Fig. 1 E). QSulf1 is also signifi-
cantly more active in [
 
35
 
S]SO
 
4
 
 release from [
 
35
 
S]GAGs than
is lysosomal GlcNR6Sase at both pH 5.5 and 7.5 (Fig. 1 F),
further distinguishing their activities.
 
QSulf1 remodels the 6-O sulfation state of HS cell 
surface in vivo
 
To investigate whether QSulf1 is enzymatically active in
vivo, we tested the effects of QSulf1 expression on 10E4
antibody immunoreactivity (IR) of cell surface HSPGs.
10E4 antibody specifically recognizes sulfated N-acetylglu-
cosamine residues (David et al., 1992; Yip et al., 2002), and
10E4 IR to cell surface HSPGs is sensitive to chlorate treat-
ment at concentrations that preferentially block 6-O sulfa-
Figure 1. QSulf1 is an HS sulfatase with substrate specificities distinct from lysosomal GlcNR6Sase. (A) QSulf1 is enzymatically active in 
[
35S]SO4 release from metabolically labeled [
35S]GAGs. [
35S]GAGs were reacted overnight (16 h) with QSulf1 in cell lysate. Myc bead–purified 
QSulf1 is similarly active. Control lysates were prepared from 293 cells transfected with either pAG empty vector (Ctrl) or a catalytic mutant 
(QSulf1[C-A]–MycHis). [
35S]SO4 release was assayed by spin column fractionation of reaction products and quantitation by scintillation counting. 
QSulf1 released  5% of total radioactivity from the [
35S]GAGs, whereas control extracts had no activity. (B) QSulf1 desulfates HS-enriched 
GAGs. CS was depleted from [
35S]GAG preparations by enzymatic digestion with chondroitinase ABC, which eliminated  22% of the 
labeled GAGs. QSulf1 released  7% of the [
35S]SO4 from HS-enriched GAGs, equivalent to the loss from total [
35S]GAG substrates. 
(C) QSulf1 does not desulfate CS-enriched GAGs. HS was depleted from [
35S]GAG preparations by enzymatic digestion with heparinases I 
and II. QSulf1 is inactive in [
35S]SO4 release from CS-enriched GAG substrate. (D) Glypican1 is a substrate for QSulf1. [
35S]Glypican1–Myc 
was prepared by metabolically labeling Glypican1–Myc-transfected cells with [
35S]SO4, followed by Myc bead purification, and subsequently 
used as the substrate in the enzymatic assay. QSulf1 released [
35S]SO4 from [
35S]Glypican1, whereas control extracts from 293 cells transfected 
with pAG empty vector or catalytic mutant QSulf1(C-A)–MycHis plasmids had no [
35S]SO4 release activity. (E) QSulf1 is inactive in 6-O 
sulfate release on monosaccharide GlcNAc6S substrates. GlcNAc6S was reacted with control, QSulf1, or lysosomal GlcNR6Sase at pH 5.5 
and 7.5, in the presence of PbCl2. QSulf1 did not desulfate GlcNAc6S, whereas lysosomal GlcNR6Sase was highly active at both pHs. 
(F) QSulf1 showed pH optima at pH 7.5. Metabolically labeled [
35S]GAGs were reacted overnight (16 h) with Ctrl, QSulf1, or lysosomal 
GlcNR6Sase at pH 5.5, 7.5, and 9.5. QSulf1 was most active in [
35S]SO4 release at pH 7.5, whereas GlcNR6Sase showed low or little activity 
toward [
35S]GAGs under these pHs.T
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tion (Safaiyan et al., 1999; Yip et al., 2002). 80% of 3T3
cells have cell surface 10E4 IR, as determined using a live
cell staining assay, and chlorate treatment reduces 10E4 IR
to 
 
 
 
20% of cells (Fig. 2, A and B). Transfected QSulf1 also
reduces 10E4 IR to a similar extent, whereas enzymatically
inactive QSulf1(C-A) has no effect. Significantly, QSulf1
does not disrupt 10E4 IR on immediately adjacent cells
(Fig. 2 A), even though QSulf1 is abundant on the surface of
expressing cells. These observations indicate that QSulf1
functions cell autonomously to remodel the sulfation states
of HSPGs on expressing cells. QSulf1 expression does not
disrupt the sulfation state of CS on the cell surface, as as-
sayed by live cell staining of QSulf1-transfected cells with a
CS-specific antibody, CS56 (Avnur and Geiger, 1984),
which recognizes sulfated epitopes also removed by chlorate
treatment (Yip et al., 2002) (Fig. 2 C). These findings sup-
port the specificity of QSulf1 for HS, as observed in bio-
chemical studies (Figs. 1, B and C).
QSulf1 also is an active 6-O endosulfatase in vivo with
similar disaccharide substrate specificities as observed in bio-
chemical assays (Table I; Fig. 3). [
 
35
 
S]GAGs were prepared
from 293 cells that were stably transfected with wild-type
and C-A mutant QSulf1 and metabolically labeled with
[
 
35
 
S]SO
 
4
 
. Disaccharide analysis shows that labeled GlcA-
Figure 2. QSulf1 desulfates cell surface HSPGs in living cells without affecting the stability of HSPG core proteins. (A) QSulf1 and chlorate 
desulfate cell surface HS, as assayed by IR to 10E4 antibody. Control 3T3 cells were transfected with empty vector, cultured with or without 
25 mM chlorate to block sulfation, and then live cell stained with 10E4 antibody, and antibody reactivity was assayed by fluorescence 
microscopy. A majority of untransfected cells (Ctrl) express 10E4 IR on the cell surface, and chlorate treatment removes 10E4 IR. Cells transfected 
with QSulf1–MycHis or catalytic mutant QSulf1(C-A)–MycHis were live stained for extracellular 10E4 IR and then permeabilized to assay 
QSulf1 or QSulf1(C-A) with a His antibody. QSulf1-expressing cells (QSulf1) lose cell surface 10E4 IR, whereas QSulf1(C-A)-expressing cells 
remain immunoreactive, as shown in the overlay. Note that QSulf1 expression does not alter 10E4 IR on adjacent cells. An asterisk marks 
transfected cells and an arrow marks cells adjacent to QSulf1-expressing cells. (B) Quantitative analysis of the effects of QSulf1 expression 
and chlorate treatment on 10E4 IR. Cells stained with 10E4 were counted, and the percentage of 10E4 IR cells was calculated as the percent 
of total cells that were 10E4 stained in the control assay (Ctrl), or as the percent of transfected cells that expressed either QSulf1 or QSulf1(C-A). 
(C) QSulf1 expression does not alter the sulfation of cell surface CS. Extracellular CS was visualized with CS56 antibody in untransfected control 
(Ctrl) cultures treated with or without chlorate or in QSulf1-transfected cultures. An asterisk marks the cells transfected with QSulf1. Assays 
were conducted in duplicate in three independent experiments, counting  100 cells in each assay. (D) The protein core of Glypican1 remains 
on the cell surface of QSulf1-expressing cells and chlorate-treated cells. 3T3 cells cotransfected with Glypican1–Myc and untagged QSulf1 
were live cell stained with Myc antibody to detect cell surface Glypican1–Myc. Cells were then permeabilized and immunostained for 
QSulf1 expression with QSulf1 antibody. Control cells were cotransfected with Glypican1–Myc and pAG empty vector plasmids, with or 
without chlorate treatment, followed by live cell staining to assay extracellular Glypican1–Myc. Similar Glypican1 staining was detected 
in control and QSulf1-transfected cells. (E) QSulf1 expression and chlorate treatment do not alter the stability or gel mobility of Glypican1. 
Western blot assays of cell extracts from 293 cells cotransfected with Glypican1–Myc, with pAG empty vector (Ctrl), QSulf1, or QSulf1(C-A) 
plasmids. Western blots were probed with anti-Myc and anti-QSulf1 antibodies.T
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GlcNS6S and IdoA2S-GlcNS6S disaccharide units were
quantitatively reduced in QSulf1-expressing cells compared
with C-A mutant controls, and this decrease is accompanied
by a parallel increase in IdoA2S-GlcNS. Disaccharide IdoA-
GlcNS6S was unchanged, establishing that QSulf1 has the
same substrate specificity in vivo as in vitro
 
.
 
 Compared with
biochemical assays, QSulf1 in vivo generated a greater de-
crease of trisulfated IdoA2S-GlcNS6S disaccharide compo-
nent (55% in vivo vs. 30% in vitro), suggesting that QSulf1
functions more efficiently in cells.
QSulf1 activity does not disrupt the accumulation of
Glypican1 HSPG core protein, which is attached on the cell
surface by a GPI linker. Immunological localization analysis
shows that QSulf1-expressing 3T3 cells and chlorate-treated
3T3 cells have abundant levels of myc-tagged Glypican1 on
these cell surfaces (Fig. 2 D). The electrophoretic mobility
and levels of Glypican1 core protein also are unchanged in
QSulf1-expressing cells, indicating that QSulf1 activity does
not lead to processing or degradation of Glypican1 core pro-
teins or its HS chains (Fig. 2 E). These findings support the
conclusion that QSulf1 activity remodels the 6-O sulfation
states of GlcA-GlcNS6S and IdoA2S-GlcNS6S disaccharide
components of HSPGs, which are retained on the cell sur-
face in their desulfated states.
 
Golgi-targeted QSulf1 is active in cell surface 
remodeling and Wnt signaling
 
During biosynthesis, QSulf1 transits through the ER and
Golgi apparatus, where HSPGs are assembled (Prydz and
Dalen, 2000), and transports together with HSPGs to the
surface of expressing cells (Dhoot et al., 2001; Ohto et al.,
2002; unpublished data). To investigate whether QSulf1 lo-
calization on the cell surface is required for its activity, we
expressed Golgi-tethered (QSulf1-Golgi) and ER-tethered
(QSulf1-ER) forms of QSulf1 in 3T3 cells and C2C12 myo-
blasts and then assayed for their biochemical and cell bio-
logical activities in remodeling the sulfation states of HS and
for Wnt induction activities. Neither QSulf1-Golgi nor
QSulf1-ER is detected on the cell surfaces of expressing cells
(unpublished data), but they colocalize with Golgi and ER
markers, respectively (Fig. 4 A). ER- and Golgi-tethered
QSulf1 isolated from expressing cells are enzymatically ac-
tive in biochemical assays for sulfate release using [
 
35
 
S]GAG
substrates (Fig. 4 B). QSulf1-ER protein is inactive in re-
modeling 10E4 IR and has little or no activity in Wnt sig-
naling, whereas the QSulf1-Golgi protein is fully active in
remodeling 10E4 IR as well as inducing Wnt signaling (Figs.
 
Table I. 
 
Summary of disaccharide analysis
Heparan sulfate O-[
 
35
 
S]–sulfated disaccharides (% of total O-[
 
35
 
S]–sulfated disaccharides)
GlcA-GlcNS6S (GMS) IdoA-GlcNS6S (IMS) IdoA2S-GlcNS (ISM) IdoA2S-GlcNS6S (ISMS)
 
QSulf1 treatment 13.0 
 
 
 
 1.0
 
a
 
6.3 
 
 
 
 1.2 50.7 
 
 
 
 3.1
 
a
 
30.0 
 
 
 
 4.6
 
a
 
QSulf1(C-A) treatment 16.0 
 
 
 
 2.0 5.0 
 
 
 
 1.0 35.3 
 
 
 
 4.5 43.7 
 
 
 
 2.3
Untreated control 19.0 
 
 
 
 3.5 4.8 
 
 
 
 1.8 33.0 
 
 
 
 4.2 43.5 
 
 
 
 0.7
QSulf1-expressing cells 14.0 
 
 
 
 1.0
 
b
 
11.0 
 
 
 
 3.6 58.0 
 
 
 
 3.0
 
a
 
17.0 
 
 
 
 3.6
 
a
 
QSulf1(C-A)-expressing cells 16.3 
 
 
 
 2.0 7.7 
 
 
 
 2.5 38.0 
 
 
 
 8.6 38.0 
 
 
 
 10.1
[
 
35
 
S]HS prepared from metabolically labeled 293T cells was reacted with Myc bead–purified QSulf1 or catalytic mutant QSulf1(C-A). Untreated control was
[
 
35
 
S]HS without treatment. To test whether QSulf1 functions in vivo, [
 
35
 
S]HS was prepared from stable 293T cell lines expressing QSulf1 or QSulf1(C-A) by
metabolic labeling with [
 
35
 
S]SO4. 
 
35
 
S-labeled disaccharides were generated by deaminative cleavage of HS, and reaction products were resolved by HPLC
anion exchange chromatography. The radioactivity in each disaccharide product was quantified by scintillation counting. Results are presented as mol-
percent of specific disaccharide products in three independent experiments. M in disaccharide abbreviations stands for the 2,5-anhydromannitol
deamination products of GlcNS residues (see also Fig. 3).
 
a
 
P 
 
 
 
 0.05 (
 
t
 
 test).
 
b
 
P 
 
 
 
 0.1.
Figure 3. QSulf1 selectively removes 6-O sulfates from HS in 
vivo. [
35S]HS prepared from metabolically labeled stable 293T cell 
lines that expressed wild-type QSulf1 and enzymatically inactive 
QSulf1(C-A) mutant was prepared for disaccharide analysis. The 
resulting disaccharide fractions were resolved by HPLC anion 
exchange chromatography and analyzed as described previously. 
The arrows correspond to the elution positions of disaccharide 
components. (A) The disaccharide components of 293T cells that 
expressed inactive QSulf1(C-A) mutant protein. (B) The disaccharide 
components of QSulf1-expressing stable 293T cell lines. GMS, 
GlcA-GlcNS6S; IMS, IdoA-GlcNS6S; ISM, IdoA2S-GlcNS; ISMS, 
IdoA2S-GlcNS6S.T
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4, C–E). These findings establish that QSulf1 plays an indi-
rect role in promoting Wnt signal transduction by remodel-
ing the 6-O sulfation states of extracellular HSPGs, either
through its activity on the cell surface or its activity in the
Golgi apparatus during HS biosynthesis.
QSulf1 regulates binding affinities of XWnt8 for HS 
chains and promotes an HS-dependent presentation 
of Wnt ligand to its Frizzled receptor
To investigate the mechanisms by which QSulf1 6-O des-
ulfation activity promotes Wnt signaling, we first tested
the activity of soluble heparin and 6-O and 2-O chemi-
cally desulfated heparin on Wnt signal transduction in
cells (Fig. 5 A). For these studies, Wnt1-expressing cells
were cocultured with Wnt1-responsive C2C12 cells trans-
fected with a TCF luciferase reporter to monitor Wnt
signaling activity. At a concentration of 10  g/ml, both
soluble heparin and 2-O–desulfated heparin completely
inhibit Wnt signaling activity, whereas 6-O–desulfated
heparin has no inhibitory effect (Fig. 5 A). Therefore, sol-
uble 6-O–sulfated HS could inhibit Wnt signaling by
blocking the Frizzled receptor from binding the Wnt
ligand. Alternatively, 6-O–sulfated HS could bind to
Wnts and prevent Wnt presentation to its Frizzled recep-
tor. To investigate whether HS blocks Frizzled receptor
activity, we compared the Wnt1 signaling activity in wild-
type CHO cells that express HSPGs and in pgsd677 mu-
tant CHO cells that are defective in HS biosynthesis (Bai
et al., 1999). Wnt1 signaling in CHO cells is dependent
on expression of a transfected Frizzled 3 (mFZ3) receptor,
which increases the response of these cells to Wnt1 by 12–
15-fold in a coculture system with Wnt1-expressing cells,
as assayed using a LEF/TCF luciferase reporter (unpub-
lished data). CHO cells are dependent on transfected
mFZ3 receptor for Wnt1 signal transduction, which
makes it possible to directly monitor the requirement for
Figure 4. Golgi-targeted QSulf1 
desulfates cell surface HSPGs and 
enhances Wnt1 signaling. (A) QSulf1
targeted to the Golgi apparatus or ER 
colocalizes with Golgi or ER markers. 
3T3 cells transfected with QSulf1-Golgi 
or QSulf1-ER were permeabilized and 
double stained with QSulf1 antibody and 
antibody against TGN 38 or ER resident 
protein PDI. QSulf1-Golgi and QSulf1-ER 
were localized in the Golgi apparatus 
and ER, respectively, as shown in overlay. 
(B) QSulf1 targeted to the Golgi apparatus 
or ER is enzymatically active on cellular 
HS substrate. QSulf1-Golgi and QSulf1-ER 
expressed in 293T cells by transient trans-
fection were incubated with [
35S]GAGs 
overnight (16 h) and released similar 
amounts of radioactivity as QSulf1. 
(C) Golgi-targeted, but not ER-targeted, 
QSulf1 decreases cell surface 10E4 IR. 
3T3 cells transfected with QSulf1-Golgi 
or QSulf1-ER were live cell stained with 
10E4 antibody to assay cell surface 10E4 
IR and then permeabilized and double 
stained with QSulf1 antibody. Expression 
of QSulf1-Golgi resulted in loss of 10E4 
IR, whereas the expression of QSulf1-ER 
had no effect on 10E4 IR, as shown in 
overlay. An asterisk marks QSulf1-trans-
fected cells. (D) QSulf1-Golgi expression 
decreases the percentage of cells with 
extracellular 10E4 IR. Cells stained with 
10E4 were counted, and the percentage 
of 10E4 IR cells was calculated as the 
percent of total cells that were 10E4 
stained in the control assay (Ctrl), or as 
the percent of transfected cells that 
expressed either QSulf1, QSulf1-Golgi, 
or QSulf1-ER. (E) QSulf1-Golgi enhances 
Wnt1 signaling activity. Lef/TCF luciferase 
reporter activity in C2C12 cells trans-
fected with empty vector as control (Ctrl), 
QSulf1, QSulf1-Golgi, or QSulf1-ER. 
Luciferase activity was normalized to 
activities of extracts from control cells 
not induced by Wnt1.T
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HS in the response of Frizzled receptor to Wnt signal. In
these mFZ3-dependent Wnt signaling assays, wild-type
and pgsd677 mutant CHO cells were found to be inactive
in Wnt1 signal transduction in the absence of Wnt1 ligand
(Fig. 5 B), whereas in response to Wnt1 ligand, mFZ3-
expressing wild-type CHO cells more actively respond to
Wnt1 than do HS-deficient pgsd677 cells (which have only
a slightly elevated response to Wnt1 compared with un-
stimulated control cells) (Fig. 5 B). These findings show
that HS does not act as a general repressor of ligand-inde-
pendent mFZ3 receptor activity. On the contrary, they
provide evidence that HS is required for efficient mFZ3
receptor activation in response to Wnt1 ligand. Therefore,
soluble sulfated heparin inhibits Wnt signaling probably
by binding to Wnt ligand and subsequently preventing the
release of the Wnt ligand to the receptor.
To investigate whether 6-O desulfation of heparin affects
Wnt binding, we developed a competition assay with hepa-
rin–agarose beads to compare the binding affinity of XWnt8
to heparin or 6-O–desulfated heparin. XWnt8 tagged with
HA is soluble and biologically active in the canonical Wnt
signaling pathway (Hsieh et al., 1999; Piccolo et al., 1999).
In this assay, HA–XWnt8 binds with high affinity to hepa-
rin–agarose beads (unpublished data), consistent with earlier
studies of Wg binding to HS (Reichsman et al., 1996). We
then tested the ability of increasing concentrations of hepa-
rin, pretreated either with QSulf1 or inactive QSulf1(C-A)
mutant protein, to release bound HA–XWnt8 from hepa-
rin–agarose beads, as assayed by Western blot analysis of
HA–XWnt8 released into the supernatant fraction (Fig. 5
C). We found that heparin treated with inactive QSulf1
(C-A) promoted the concentration-dependent release of HA–
XWnt8 from heparin beads; by contrast, QSulf1-treated
heparin released only small amounts of HA–XWnt8, and
this release was not concentration dependent, reflecting low
affinity binding of HA–XWnt8 to 6-O–desulfated heparin
(Fig. 5 C).
The activity of QSulf1 in Wnt binding to HS was also
tested in XWnt8 binding to Glypican1, a cell surface
HSPG that mediates Wnt signaling (Lin and Perrimon,
1999; Tsuda et al., 1999; Baeg et al., 2001). A soluble
form of Glypican1 tagged with alkaline phosphatase (AP)
was used in the binding assay to allow Glypican1 purifica-
tion from the media of transfected cells (Chen and Lander,
2001). HA-tagged XWnt8 was incubated with the soluble
Glypican1–AP, and complexes formed were immuno-
Figure 5. QSulf1 regulates the inter-
action between HS and Wnt ligand to 
promote Wnt signaling. (A) 6-O–
desulfated heparin does not inhibit Wnt 
signaling. C2C12 cells transfected with 
Tcf/LEF luciferase reporter to monitor 
Wnt signaling activity were stimulated 
by Wnt1-secreting cells in the presence 
of heparin or chemically 2-O–desulfated 
or 6-O–desulfated heparin. Luciferase 
activity was normalized to activities from 
cells cultured without heparin. 6-O–
desulfated heparin had no effect on Wnt 
signaling, whereas heparin or 2-O–
desulfated heparin completely inhibited 
Wnt signaling activity at a concentration 
of 10  g/ml. (B) HS is required for Frizzled 
3 receptor activation by Wnt1. Wild-type 
CHO cells or HS-deficient pgsd677 
mutant CHO cells were transfected with 
a Frizzled 3 expression vector to initiate 
Wnt signaling. Expression of Frizzled 3 
receptor alone did not activate Wnt 
signaling in wild-type CHO cells or 
mutant pgsd677 cells. Mutant pgsd677 
cells are defective in Wnt1 signaling. 
(C) QSulf1 activity reduces the binding 
affinity between heparin and XWnt8. 
Heparin pretreated with QSulf1 or 
inactive QSulf1(C-A) mutant was incu-
bated with HA–XWnt8 that was bound 
to heparin–agarose beads. The released 
HA–XWnt8 in the supernatant was 
measured by Western blot. Heparin treated with inactive QSulf1(C-A) mutant released HA–XWnt8 in a concentration-dependent manner, 
whereas QSulf1-desulfated heparin released much less HA–XWnt8. QSulf1 treatment reduced the competitive activity of heparin for HA–XWnt8 
release consistently in four experiments, although the quantitative extent of research varied. (D) QSulf1 decreased XWnt8 binding to Glypican1. 
Glypican1–AP was treated by QSulf1, inactive QSulf1(C-A) mutant, or heparinase and then incubated with HA–XWnt8 to allow the binding. 
Glypican1-AP–HA-XWnt8 complex was separated by immunoprecipitation with AP antibodies and then analyzed by Western blot. QSulf1(C-A)-
treated Glypican1 bound more HA–XWnt8 than QSulf1-treated Glypican1, and the binding was abolished by heparinase treatment. (E) QSulf1 
decreased the binding of Glypican1 to HA–XWnt8-expressing cells. Glypican1–AP pretreated with either QSulf1 or QSulf1(C-A) was incubated 
with XWnt8-expressing cells. The bound Glypican1–AP on the cell surface was visualized by AP substrate staining.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
348 The Journal of Cell Biology | Volume 162, Number 2, 2003
precipitated by agarose beads coupled with monoclonal
AP antibodies, followed by probing Western blots of pro-
tein complexes with HA-specific antibodies (Fig. 5 D).
Pretreatment of Glypican1 with heparinase completely
blocked its binding to XWnt8, establishing that XWnt8
binding to Glypican1 is mediated through the HS chains
and not the protein core. QSulf1 treatment of Glypican1–
AP significantly diminished, but did not completely block,
formation of HA–XWnt8 binding, compared with treat-
ment with C-A mutant QSulf1, which did not diminish
complex formation (Fig. 5 D). QSulf1 treatment also
blocked the binding of Glypican1–AP to XWnt8 expressed
on the surface of living transfected 293T cells, as detected
by immunohistochemical detection in a cell binding as-
say (Hsieh et al., 1999; Wu and Nusse, 2002), whereas
QSulf1(C-A) treatment did not prevent binding (Fig. 5 E).
Control and C-A mutant QSulf1–treated Glypican1–AP
abundantly bound to the surfaces of HA–XWnt8-express-
ing cells, as detected by double immunostaining with HA
antibodies (unpublished data). Together, these Wnt bind-
ing studies reveal that QSulf1 6-O sulfatase activity re-
duces the binding of Wnt to HS on Glypican1. The results
of these binding studies are consistent with a two-state
catch or presentation model (Fig. 6) in which 6-O–sulfated
HS on cell surface HSPGs binds Wnts in a high affinity
state to “catch” Wnt ligands and compete with the binding
of Wnts to Frizzled receptor (Fig. 6 A). The HS 6-O de-
sulfation activity of QSulf1 would convert the cell surface
HS to a low affinity binding state for Wnts, which allows
their HS-dependent “presentation” to the Frizzled recep-
tors to initiate Wnt signal transduction (Fig. 6 B). By this
mechanism, QSulf1, which is expressed in localized popu-
lations of somite and neural progenitor cells, would pattern
Wnt signaling responses to localized populations of pro-
genitors responding to widely dispersed Wnt signals.
Discussion
Our biochemical and cell expression studies identify QSulf1
as an HS-specific 6-O endosulfatase with substrate specific-
ity for disulfated GlcA-GlcNS6S and trisulfated IdoA2S-
GlcNS6S disaccharide components of cellular HS chains.
QSulf1 does not appear to desulfate -IdoA-GlcNS6S- se-
quences, providing evidence for functional selectivity of
QSulf1 activities. Also, QSulf1, both in vitro and in vivo,
desulfates only a small fraction of GlcA-GlcNS6S disaccha-
ride residues, suggesting that QSulf1 is active with only a
subset of GlcA-GlcNS6S residues in HS chains. Compared
with its low activity on GlcA-GlcNS6S residues, QSulf1 in-
duces appreciable 6-O desulfation of trisulfated IdoA2S-
GlcNS6S units, which are major sulfated constituents of
cellular HS chains. These findings are consistent with im-
munochemical studies with 10E4 antibody in which we show
that QSulf1 expression remodels the 10E4 IR on the surface
of expressing cells. HSulf1 and HSulf2, human orthologues
of QSulf1, also desulfate -IdoA2S-GlcNS6S- units on intes-
tinal heparin (Morimoto-Tomita et al., 2002). Heparin is
enriched in IdoA and O-sulfation, in contrast to cell-derived
HS, which contains more GlcA and has less 2-O–sulfated
sugars (Vives et al., 1999), which accounts for our identifica-
tion of GlcA-GlcNS6S as a QSulf1 substrate. The substrate
specificity and high level activity of QSulf1 on cell-derived
HS establish QSulf1 as a unique 6-O endosulfatase that re-
moves 6-O sulfates from sulfated residues located within HS
chains, in contrast to lysosomal GlcNR6Sase, which is an
exosulfatase involved in the sequential degradation of HS
chains (Kresse et al., 1980).
QSulf1 6-O endosulfatase activity for disulfated GlcA-
GlcNS6S and trisulfated IdoA2S-GlcNS6S disaccharide
components of cellular HS chains attenuates the binding af-
finity of XWnt8 ligand to HS chains on Glypican1, which
plays a central role in developmental signaling (Lin and Perri-
Figure 6. A two-state catch or presentation model of QSulf1 regulation of Wnt signaling. (A) In QSulf1-nonexpressing embryonic cells, HS 
chains on cell surface HSPGs are in a 6-O–sulfated state, which binds with high affinities to catch Wnt ligands, preventing functional interactions 
of bound Wnts with their Frizzled receptors. (B) In QSulf1-expressing cells, selective 6-O desulfation activity of QSulf1 removes 6-O sulfates 
from HS chains on cell surface HSPGs to convert HS to a low affinity binding state for Wnts. 6-O–desulfated HS then can present Wnt ligands 
to Frizzled receptor and can form functionally active Wnt–HS–Frizzled receptor complexes for initiation of Wnt signal transduction.T
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mon, 1999; Tsuda et al., 1999; Baeg et al., 2001; Nybakken
and Perrimon, 2002), leading to stimulation of Wnt signal-
ing. Although the specific structural interactions between
Wnt ligand and HS residues are not yet known, it is notable
that the trisulfated IdoA2S-GlcNS6S disaccharide contrib-
utes directly to the high affinity binding of bFGF to HS, and
the 6-O sulfate of this trisulfated disaccharide is required
for  FGF-dependent receptor dimerization and activation
(Schlessinger et al., 2000; Pye et al., 2000). These observa-
tions predict that QSulf1 activity will block HS-dependent
FGF signaling, in contrast to Wnt signaling, which is stimu-
lated by QSulf1 (Dhoot et al., 2001). QSulf1, therefore, may
have a dual developmental function as a positive regulator of
Wnt signaling and a negative regulator of FGF signaling.
Our findings provide evidence that QSulf1 plays a positive
role in the regulation of Wnt signaling. QSulf1 is tethered to
the cell surface and cell autonomously remodels the 6-O sul-
fation of extracellular HSPGs of Wnt-responsive somite and
neural progenitors in embryos (Dhoot et al., 2001). Notum
is another HSPG-modifying enzyme that regulates Wnt sig-
naling in embryos (Giraldez et al., 2002). However, in con-
trast to QSulf1, Notum is released from Wg-producing cells
to establish a morphogen gradient of Wg ligand presumably
through its activity to degrade HS on HSPGs. Drosophila
Notum mutants show much expanded Wg distribution and
enhanced Wg activity in embryonic patterning, suggesting
that Notum negatively regulates Wg signaling in Wg-respon-
sive cells. By contrast, QSulf1 positively regulates Wnt sig-
naling when localized either on the cell surface or targeted to
the Golgi apparatus by actively remodeling the 6-O sulfation
states of HS chains, which does not degrade HS or promote
the turnover of HSPG core protein.
Our study of QSulf1 activity on Wnt binding to HS sheds
light on the mechanism of QSulf1 function in Wnt signal-
ing. We show that soluble 6-O–sulfated heparin binds to
Wnt ligand with high affinity and strongly inhibits Wnt sig-
naling. QSulf1 significantly reduces, but does not eliminate,
the binding of XWnt8 to HS through its 6-O endosulfatase
activity to promote Wnt signaling. Selective 6-O desulfation
by QSulf1 does not remove all sulfates from HS. The resid-
ual sulfated residues on QSulf1-desulfated HS are essential
for HS-mediated transduction of Wnt signals and Frizzled
activation, based on previous findings that complete loss of
HS sulfation in sulfateless mutant Drosophila or by chlorate
treatment blocks Wnt signaling (Reichsman et al., 1996; Lin
and Perrimon, 1999; Dhoot et al., 2001; Toyoda et al.,
2000). CHO cells deficient in HS biosynthesis are also de-
fective in Frizzled-dependent Wnt signaling, further estab-
lishing that HS is required for Frizzled function. Our find-
ings also reveal that QSulf1 targeted to the cell surface or the
Golgi apparatus actively remodels the sulfation states of cell
surface HSPGs and promotes Wnt signaling. Therefore,
QSulf1 itself does not function dynamically in the presenta-
tion of Wnt ligands to Frizzled receptors, but rather selec-
tively removes 6-O sulfates from HS on the cell surface to
convert the HS from a high affinity binding state to a low af-
finity binding state to allow the formation of functional
Wnt–Frizzled complexes. Together, these findings support a
static two-state catch or presentation model for QSulf1 reg-
ulation of Wnt signaling (Fig. 6). According to this model,
embryonic cells that do not express QSulf1 would have sul-
fated HSPGs on the cell surface in a high affinity state that
catch Wnts and compete for binding of Wnts to their Friz-
zled receptors. QSulf1 expression in localized populations of
embryonic progenitors would reduce 6-O HS sulfation to
lower the binding affinity between Wnts and HSPGs, and
6-O–desulfated HS in the low affinity binding state would
present Wnt ligand to promote the formation of Wnt–Friz-
zled receptor complexes to initiate Wnt signaling. In this re-
gard, it is interesting to note that Frizzled-related proteins,
such as sFRP-1, have heparin-binding domains that pro-
mote the formation of sFRP-1 and Wg complexes (Chong et
al., 2002), suggesting that Wnts interacting with QSulf1-
desulfated HS chains form a ternary complex with the Friz-
zled receptor, similar to the FGF–HS–FGFR complex that
is required to initiate FGF signaling (Schlessinger et al.,
2000). Therefore, the presentation of Wnt ligand by 6-O–
desulfated HS in the low affinity binding state would pro-
vide a static mechanism to promote Wnt–Frizzled interac-
tion in QSulf1-expressing cells. However, we also show that
soluble heparin blocks Wnt signaling, suggesting that trisul-
fated HS may immobilize Wnt ligand on the cell surface,
and QSulf1 activity reduces Wnt binding affinity of HS to
enhance the access of Wnt ligand to Frizzled receptor, as
shown by biochemical binding assays. We also show that
chemically 6-O–desulfated soluble heparin does not pro-
mote Wnt signaling, suggesting that the residual 6-O sulfate
groups on QSulf1-desulfated HS may be involved in Wnt
binding to its Frizzled receptor. Structural studies of the in-
teractions of QSulf1-modified HS substrates with Wnt
ligands and their Frizzled receptors will provide insights into
the specific mechanisms by which QSulf1 activity regulates
Wnt signaling and will provide a basis for the development
of therapeutic reagents to attenuate pathological HSPG-
dependent signaling responses through control of angiogen-
esis and cell migration in diseases such as cancer (Sasaki et
al., 1999; Lundin et al., 2000; Selva and Perrimon, 2001).
Materials and methods
Expression plasmids
QSulf1 and Glypican1 were cloned in pAG expression vector with a Myc-
His COOH-terminal tag. The expression vector for a soluble form of
Glypican1–AP lacking GPI linkage groups was provided by A. Lander
(University of California, Irvine, CA) (Chen and Lander, 2001). HA–XWnt8
was cloned into pCS2 expression vector (Piccolo et al., 1999). QSulf1-ER
expression vector was constructed by replacing the COOH-terminal Myc-
His tag with a KDEL coding sequence (Munro and Pelham, 1987). QSulf1-
Golgi expression plasmid was constructed by replacing the NH2-terminal
signal peptide of QSulf1 (amino acids 1–21) with NH2-terminal amino ac-
ids 1–81 of the human   1,4-galactosyltransferase (Gleeson et al., 1994).
pECFP-Golgi and pECFP-ER were used as transfection markers to assay
Golgi apparatus and ER expression (CLONTECH Laboratories, Inc.).
Cell culture and DNA transfection
All cell lines were cultured in DME with 10% FBS (Invitrogen). Cells were
transfected with Fugene 6 (Roche) in 24-well plates for immunohistologi-
cal analysis and Wnt1 assays, as described previously (Dhoot et al., 2001).
QSulf1, Glypican1, Glypican1–AP, and XWnt8 proteins were expressed in
293T cells cultured in 100-mm dishes using a standard lipofectamine
transfection protocol (Invitrogen). Stable QSulf1-expressing 293T cell lines
were generated by selecting transfected 293T cells with 250  g/ml hy-
gromycin (Sigma-Aldrich) 48 h after transfection. Expressed proteins, in-
cluding QSulf1, Glypican1, and HA–XWnt8, were extracted from cells
24 h after transfection. To produce Glypican1–AP, transfected cells wereT
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switched to serum-free DME/F12 (Invitrogen) 24 h after transfection, and
conditioned medium was collected 16 h later. Protein expression was
monitored by Western blot electrophoresis, followed by enzymatic or
binding assays, as described below. As noted, chlorate-treated cultures
were incubated with 25 mM chlorate for 18 h before being processed for
immunocytochemistry and Western blot analysis.
Preparation of [
35S]GAG substrates
Confluent 293T cell cultures in 100-mm dishes, either untransfected or sta-
ble lines expressing QSulf1 or control proteins, were transferred to low sul-
fate F12 medium with 1% FBS and metabolically labeled for 5 h in 100
 Ci/ml of carrier-free [
35S]SO4 (NEN Life Science Products). After rinsing
with TBS, cells were lysed in 0.25% Triton X-100, followed by overnight
digestion with proteinase K (10  g/ml; Sigma-Aldrich) at 55 C. Proteinase
K was then heat inactivated, and [
35S]GAGs were precipitated in three vol-
umes of 95% ethanol, 1  g/ml dermatan sulfate (Sigma-Aldrich), and 1/10
volume of 5 M NaAc overnight at  20 C. After centrifugation, the
[
35S]GAG pellet was air dried, dissolved in water, and then centrifuged in a
5-kD filter unit (UFC3BCC00; Millipore) to remove molecules with molec-
ular masses  5 kD. [
35S]GAGs were reconstituted in water at a concentra-
tion of 10
7 cpm/ml for use as substrates in QSulf1 enzyme assays or di-
rectly for disaccharide assays. To differentially deplete [
35S]GAGs of HS or
CS, samples were digested for 4 h at 37 C with either heparinases I and
II (0.1 U/ml; Sigma-Aldrich) or chondroitinase ABC (0.1 U/ml; Sigma-
Aldrich), followed by heat inactivation. Prior to enzyme assays, low mo-
lecular mass digestion products were removed from heparinase- and chon-
droitinase-treated [
35S]GAG preparations by centrifugation in 5-kD filter
units.
QSulf1 enzyme assays
293T cell cultures transfected with Myc-tagged QSulf1 and control plas-
mids were lysed in 500  l of 0.25% Triton X-100. Freshly prepared cell ly-
sates were dialyzed in TBS to remove phosphate and sulfate and other
small molecules or incubated overnight with Myc beads (CLONTECH Lab-
oratories, Inc.) at 4 C. Myc beads were then washed and resuspended
in TBS. QSulf1–Myc was purified 15–20-fold by incubation with Myc
beads, as assayed by Western blot analysis. QSulf1 enzyme assays with
[
35S]GAGs were conducted in 200- l reaction mixtures, including 30  l of
cell lysate (10  g) or Myc bead–purified enzyme (0.5  g), 10  l of
[
35S]GAG substrate in 50 mM Tris buffer (pH 7.5), and 50 mM MgCl2. Sam-
ples were digested overnight at 37 C. Enzyme reactions were 95% com-
plete after 4 h. After incubation, the reaction mixture was centrifuged to re-
move Myc beads and denatured proteins, and the released, low molecular
mass [
35S]SO4 was assayed by centrifugation of samples at 14,000 rpm for
30 min using the 5-kD filter unit, followed by scintillation counting for
quantization of [
35S]SO4 release. Assays with N-acetylglucosamine 6-O
sulfate monosaccharide substrate (Sigma-Aldrich) were modified from pre-
viously described assays by the addition of 50 mM MgCl2 and 3 mM PbCl2
to reactions (He et al., 1993). N-acetylglucosamine formation was mea-
sured by the Reissig method (Reissig et al., 1955). Control extracts for en-
zymatic assays with [
35S]GAG and GlcNAc6S substrates were prepared
from 293 cells transfected with empty vector or mutant QSulf1(C-A) ex-
pression plasmids.
Structural analysis of 
35S-labeled HS
HS chains were cleaved at N-sulfated glucosamine residues by treatment
with nitrous acid at pH 1.5 (Shively and Conrad, 1976), followed by re-
duction with NaBH4. Labeled deamination products were fractionated by
gel chromatography on a column (1   180 cm) of Sephadex G-25 eluted
with 0.2 M NH4HCO3. Samples of isolated disaccharides were analyzed
on a Partisil-10 SAX column eluted at a rate of 1 ml/min with stepwise in-
creasing concentrations of KH2PO4 (Rong et al., 2001).
Immunocytochemistry and Western blots
Cells for immunochemical analysis were cultured on acid-treated cover-
slips. To assay cell surface markers, cells were live cell stained by incubat-
ing cells with the primary antibody in culture medium for 2 h at 37 C,
rinsed with PBS, and then permeabilized by fixation with 4% paraformal-
dehyde/PBS at room temperature for 15 min for immunostaining to identify
QSulf1–MycHis-expressing cells. After washing, cells were incubated for
2 h with the secondary antibody or double stained in antibody dilution
buffer (0.1% Triton X-100 in PBS, 20% goat serum). Cells were subse-
quently washed with PBS, and coverslips were mounted and analyzed by
fluorescence microscopy. Western blots were prepared as described previ-
ously (Dhoot, et al., 2001). The primary antibodies used included mouse
anti-Myc (9E10; 1:300 for immunocytochemistry and 1:2,000 for Western
blots), rabbit anti-His (1:200; Santa Cruz Biotechnology, Inc.), mouse anti-
HS (10E4; 1:150; Seikagaku), mouse anti-CS (CS56; 1:100; Sigma-Aldrich),
rabbit anti–QSulf1 hydrophilic domain (1:200 for immunostaining and
1:2,000 for Western blotting; Calico), mouse anti–TGN 38 (Ab-1; 1:1,000;
Oncogene); mouse anti-PDI (1:100; Affinity BioReagents, Inc.), mouse
anti–alkaline phosphatase (8B6; 1:4,000; Sigma-Aldrich), and mouse
anti-HA (1:1,000; CLONTECH Laboratories, Inc.). Secondary antibodies
included goat anti–mouse Cy3 (1:1,000; Jackson ImmunoResearch Labora-
tories), goat anti–rabbit Cy2 (1:1,000; Jackson ImmunoResearch Laborato-
ries), peroxidase-conjugated goat anti–mouse (diluted 1:4,000; Vector
Laboratories), peroxidase-conjugated goat anti–rabbit (diluted 1:4,000;
Vector Laboratories).
Binding assay for HA–XWnt8- or HA–XWnt8-expressing cells
To produce HA–XWnt8, 293T cell cultures transfected with HA–XWnt8
expression plasmid were lysed in 500  l of 0.25% Triton X-100. The cell
lysate was spun for 5 min to separate the nuclei, and the supernatant was
collected. NaCl was added to the supernatant to a final concentration of
2 M to salt off any membrane-bound HA–XWnt8, and extra NaCl in the cell
lysate was diluted by dialysis overnight at 4 C in PBS. To generate soluble
Glypican1–AP, conditioned medium collected from transfected cells was
concentrated 100-fold through 10-kD Centriprep (Amicon) columns, and
the amount of concentrated proteins was quantified using a colormetric
dye concentrate reagent (Bio-Rad Laboratories). The concentrated proteins
containing Glypican1–AP were treated with QSulf1 or control overnight.
For binding to HA–XWnt8, 50  g concentrated protein was immunopre-
cipitated after enzymatic treatment using 50  l AP beads (CLONTECH
Laboratories, Inc.). The beads were then separated by centrifugation and
washed with HBSS with 20 mM Hepes (pH 7.0). An aliquot of 10  l beads
with bound Glypican1–AP was incubated with HA–XWnt8 for 20 min at
RT. After centrifugation and washes, the beads were collected, and HA–
XWnt8 bound to Glypican1–AP was quantified by Western blot. For bind-
ing to HA–XWnt8-expressing cells, Glypican1–AP treated with either
QSulf1 or control was added to 293T cells transfected with HA–XWnt8 ex-
pression vector at a concentration of  50  g/ml. The protocol for the
binding was performed as previously described (Hsieh et al., 1999).
Competition assay for HA–XWnt8 binding to heparin
Heparin immobilized on 100  l agarose beads (Sigma-Aldrich) was
blocked with 0.5 mg/ml BSA in HBSS with 20 mM Hepes (pH 7.0) at RT
for 1 h, followed by incubation with 400  l HA–XWnt8 at RT for 30 min.
Heparin beads were separated by centrifugation and washed three times
with HBSS with 20 mM Hepes (pH 7.0), and equal quantities were then al-
iquoted into 10 tubes. Heparin was treated overnight either with QSulf1 or
control QSulf1(C-A) mutant proteins and then added to heparin beads to
compete for HA–XWnt8 binding. After 30 min at RT, heparin beads were
separated by centrifugation, and HA–XWnt8 in the supernatant was quan-
tified by Western blot. The intensity of protein corresponding to HA–
XWnt8 protein on Western blots was quantified by IQuant.
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